Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Purchased by Sumitomo Mitsui DS Asset Management Company Ltd

Sumitomo Mitsui DS Asset Management Company Ltd increased its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 27.6% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 12,114 shares of the biopharmaceutical company's stock after purchasing an additional 2,619 shares during the quarter. Sumitomo Mitsui DS Asset Management Company Ltd's holdings in Alnylam Pharmaceuticals were worth $2,944,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of ALNY. Allspring Global Investments Holdings LLC grew its position in shares of Alnylam Pharmaceuticals by 572.0% in the first quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company's stock valued at $25,000 after purchasing an additional 143 shares during the period. Altitude Crest Partners Inc. acquired a new stake in Alnylam Pharmaceuticals in the 1st quarter worth about $30,000. GAMMA Investing LLC purchased a new stake in Alnylam Pharmaceuticals during the 4th quarter worth approximately $52,000. V Square Quantitative Management LLC purchased a new stake in Alnylam Pharmaceuticals during the 4th quarter worth approximately $52,000. Finally, Benjamin F. Edwards & Company Inc. acquired a new position in shares of Alnylam Pharmaceuticals during the fourth quarter valued at approximately $71,000. Hedge funds and other institutional investors own 92.97% of the company's stock.

Alnylam Pharmaceuticals Price Performance

Shares of ALNY stock traded down $24.32 during trading hours on Friday, hitting $262.69. The company had a trading volume of 3,762,558 shares, compared to its average volume of 901,792. The stock has a market capitalization of $33.23 billion, a PE ratio of -98.02 and a beta of 0.37. The company's fifty day moving average is $255.96 and its 200 day moving average is $187.51. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $141.98 and a fifty-two week high of $287.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.13) EPS for the quarter, topping analysts' consensus estimates of ($0.74) by $0.61. The firm had revenue of $659.83 million for the quarter, compared to analyst estimates of $447.22 million. During the same quarter last year, the company earned ($2.21) earnings per share. The firm's revenue for the quarter was up 107.0% on a year-over-year basis. Equities analysts forecast that Alnylam Pharmaceuticals, Inc. will post -3.99 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on ALNY. Wells Fargo & Company lifted their price target on Alnylam Pharmaceuticals from $207.00 to $233.00 and gave the stock an "equal weight" rating in a research note on Friday, August 2nd. Bank of America upped their target price on shares of Alnylam Pharmaceuticals from $248.00 to $295.00 and gave the stock a "buy" rating in a report on Tuesday, June 25th. UBS Group raised their price target on shares of Alnylam Pharmaceuticals from $253.00 to $288.00 and gave the stock a "buy" rating in a research note on Friday, June 28th. Chardan Capital reaffirmed a "buy" rating and set a $225.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Friday, May 3rd. Finally, Citigroup raised their target price on shares of Alnylam Pharmaceuticals from $291.00 to $342.00 and gave the stock a "buy" rating in a research note on Friday, August 2nd. Seven equities research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the stock. According to data from MarketBeat.com, Alnylam Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus price target of $278.59.

Insider Activity at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, Director David E. I. Pyott sold 32,450 shares of the business's stock in a transaction dated Monday, June 24th. The shares were sold at an average price of $220.69, for a total transaction of $7,161,390.50. Following the sale, the director now directly owns 136 shares in the company, valued at $30,013.84. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Alnylam Pharmaceuticals news, Director David E. I. Pyott sold 32,450 shares of the firm's stock in a transaction that occurred on Monday, June 24th. The shares were sold at an average price of $220.69, for a total value of $7,161,390.50. Following the completion of the transaction, the director now owns 136 shares of the company's stock, valued at approximately $30,013.84. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Yvonne Greenstreet sold 15,000 shares of the business's stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $280.00, for a total transaction of $4,200,000.00. Following the completion of the transaction, the chief executive officer now owns 73,441 shares of the company's stock, valued at approximately $20,563,480. The disclosure for this sale can be found here. Insiders sold 103,148 shares of company stock worth $25,658,824 in the last three months. 1.50% of the stock is owned by company insiders.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.